<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04095546</url>
  </required_header>
  <id_info>
    <org_study_id>2019-00658; pk19Zimmermann</org_study_id>
    <nct_id>NCT04095546</nct_id>
  </id_info>
  <brief_title>Epigenetic Changes in Psychotherapy of Adolescents With Borderline Personality Pathology</brief_title>
  <official_title>Epigenetic Changes in Psychotherapy of Adolescents With Borderline Personality Pathology</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Leading House for the Latin American Region (Seed Money Grant SMG 1730)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The link between epigenetic changes as an effect of psychotherapy has been investigated
      recently. Genes investigated in these studies were brain-derived neurotrophic factor (BDNF),
      NR3C1, FKBP51, MAOA and GLUT1. Change in methylation of these genes could be a biomolecular
      mechanism of psychotherapy induced changes. This study project aims at providing evidence for
      a biological mechanism of personality disorder interventions in adolescence by investigating
      the link between epigenetic changes as an effect of psychotherapy. It investigates the
      correlation between changes in the methylation of the FKBP5 gene and psychotherapy induced
      changes in symptoms and functioning.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2020</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">February 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>change in methylation of the FKBP5 gene</measure>
    <time_frame>after 6 months from baseline</time_frame>
    <description>change in methylation of the FKBP5 gene</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in methylation of the FKBP5 gene</measure>
    <time_frame>at month 3 and at month 12 after baseline.</time_frame>
    <description>change in methylation of the FKBP5 gene</description>
  </secondary_outcome>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Borderline Personality Disorder (BPD)</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>routine psychotherapy for Borderline Personality Disorder (BPD)</intervention_name>
    <description>Routine psychotherapy as treatment for patients with Borderline Personality Disorder</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients in Basel/ Switzerland will be recruited from the routine clinical practice of the
        Outpatient Department of the Child and Adolescent Psychiatric Hospital.

        Patients in Santiago/ Chile will be recruited from the Department of Psychiatry and Mental
        Health, East Campus,Faculty of Medicine, University of Chile.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  adolescents presenting 3 or more criteria for BPD in the Structured clinical interview
             for the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) axis II
             personality disorders (SCID-II)

        Exclusion Criteria:

          -  difficulties to understand or comply with instructions

          -  psychotic disorders

          -  pervasive developmental disorders

          -  severe somatic or neurological disorders

          -  severe and persistent substance addiction

          -  elevated risk for complications related to blood sampling
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronan Zimmermann, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kinder- und Jugendpsychiatrische Klinik/Universitäre Psychiatrische Klinken Basel (UPK)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ronan Zimmermann, PhD</last_name>
    <phone>+41 061 704 12 12</phone>
    <email>ronan.zimmermann@unibas.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Oliver Pick, Dr. med</last_name>
    <phone>+41 61 325 82 00</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Psychiatry and Mental Health, East Campus,</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
    <contact>
      <last_name>Yamil Quevedo Labbé, MD</last_name>
      <phone>229770528</phone>
      <email>yamilquevedo@ug.uchile.cl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Child and Adolescent Psychiatric Hospital, University Psychiatric Hospitals of the University of Basel</name>
      <address>
        <city>Basel</city>
        <zip>4056</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <contact>
      <last_name>Ronan Zimmermann, PhD</last_name>
      <phone>: +41 061 704 12 12</phone>
      <email>ronan.zimmermann@unibas.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Chile</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>September 17, 2019</study_first_submitted>
  <study_first_submitted_qc>September 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 19, 2019</study_first_posted>
  <last_update_submitted>April 2, 2020</last_update_submitted>
  <last_update_submitted_qc>April 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>epigenetic changes</keyword>
  <keyword>Psychotherapy</keyword>
  <keyword>epigenetic regulation</keyword>
  <keyword>methylation patterns</keyword>
  <keyword>change in methylation of genes</keyword>
  <keyword>FKBP5 gene</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Personality Disorders</mesh_term>
    <mesh_term>Borderline Personality Disorder</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

